Loteprednol Etabonate Patent Expiration
Loteprednol Etabonate is Used for treating steroid-responsive conditions in the eye, such as inflammation of the conjunctiva, cornea, and anterior segment. It was first introduced by Bausch And Lomb Inc
Loteprednol Etabonate Patents
Given below is the list of patents protecting Loteprednol Etabonate, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Alrex |
US4996335 (Pediatric) | Soft steroids having anti-inflammatory activity |
Sep 09, 2012
(Expired) | Bausch And Lomb |
| Alrex | US5540930 | Suspension of loteprednol etabonate for ear, eye, or nose treatment |
Oct 25, 2013
(Expired) | Bausch And Lomb |
| Alrex |
US5540930 (Pediatric) | Suspension of loteprednol etabonate for ear, eye, or nose treatment |
Apr 25, 2014
(Expired) | Bausch And Lomb |
| Alrex | US5747061 | Suspension of loteprednol etabonate for ear, eye, or nose treatment |
Oct 25, 2013
(Expired) | Bausch And Lomb |
| Alrex |
US5747061 (Pediatric) | Suspension of loteprednol etabonate for ear, eye, or nose treatment |
Apr 25, 2014
(Expired) | Bausch And Lomb |
| Eysuvis | US10058511 | Nanocrystals, compositions, and methods that aid particle transport in mucus | May 03, 2033 | Alcon Labs Inc |
| Eysuvis | US10646436 | Compositions and methods for ophthalmic and/or other applications | May 03, 2033 | Alcon Labs Inc |
| Eysuvis | US10688045 | Compositions and methods for ophthalmic and/or other applications | May 03, 2033 | Alcon Labs Inc |
| Eysuvis | US10857096 | Compositions and methods for ophthalmic and/or other applications | May 03, 2033 | Alcon Labs Inc |
| Eysuvis | US10940108 | Compositions and methods for ophthalmic and/or other applications | May 03, 2033 | Alcon Labs Inc |
| Eysuvis | US10945948 | Compositions and methods for ophthalmic and/or other applications | May 03, 2033 | Alcon Labs Inc |
| Eysuvis | US10993908 | Compositions and methods for ophthalmic and/or other applications | May 03, 2033 | Alcon Labs Inc |
| Eysuvis | US11219596 | Compositions and methods for ophthalmic and/or other applications | May 03, 2033 | Alcon Labs Inc |
| Eysuvis | US11596599 | Compositions and methods for ophthalmic and/or other applications | May 03, 2033 | Alcon Labs Inc |
| Eysuvis | US11642317 | Nanocrystals, compositions, and methods that aid particle transport in mucus | May 03, 2033 | Alcon Labs Inc |
| Eysuvis | US11872318 | Nanocrystals, compositions, and methods that aid particle transport in mucus | May 03, 2033 | Alcon Labs Inc |
| Eysuvis | US9056057 | Nanocrystals, compositions, and methods that aid particle transport in mucus | May 03, 2033 | Alcon Labs Inc |
| Eysuvis | US9393213 | Nanocrystals, compositions, and methods that aid particle transport in mucus | May 03, 2033 | Alcon Labs Inc |
| Eysuvis | US9532955 | Nanocrystals, compositions, and methods that aid particle transport in mucus | May 03, 2033 | Alcon Labs Inc |
| Eysuvis | US9737491 | Nanocrystals, compositions, and methods that aid particle transport in mucus | May 03, 2033 | Alcon Labs Inc |
| Eysuvis | US9827191 | Compositions and methods for ophthalmic and/or other applications | May 03, 2033 | Alcon Labs Inc |
| Inveltys | US10058511 | Nanocrystals, compositions, and methods that aid particle transport in mucus | May 03, 2033 | Alcon Labs Inc |
| Inveltys | US10646437 | Compositions and methods for ophthalmic and/or other applications | May 03, 2033 | Alcon Labs Inc |
| Inveltys | US10688045 | Compositions and methods for ophthalmic and/or other applications | May 03, 2033 | Alcon Labs Inc |
| Inveltys | US10864219 | Compositions and methods for ophthalmic and/or other applications | May 03, 2033 | Alcon Labs Inc |
| Inveltys | US11219597 | Compositions and methods for ophthalmic and/or other applications | May 03, 2033 | Alcon Labs Inc |
| Inveltys | US11642317 | Nanocrystals, compositions, and methods that aid particle transport in mucus | May 03, 2033 | Alcon Labs Inc |
| Inveltys | US11872318 | Nanocrystals, compositions, and methods that aid particle transport in mucus | May 03, 2033 | Alcon Labs Inc |
| Inveltys | US9056057 | Nanocrystals, compositions, and methods that aid particle transport in mucus | May 03, 2033 | Alcon Labs Inc |
| Inveltys | US9393213 | Nanocrystals, compositions, and methods that aid particle transport in mucus | May 03, 2033 | Alcon Labs Inc |
| Inveltys | US9532955 | Nanocrystals, compositions, and methods that aid particle transport in mucus | May 03, 2033 | Alcon Labs Inc |
| Inveltys | US9737491 | Nanocrystals, compositions, and methods that aid particle transport in mucus | May 03, 2033 | Alcon Labs Inc |
| Inveltys | US9827191 | Compositions and methods for ophthalmic and/or other applications | May 03, 2033 | Alcon Labs Inc |
| Lotemax |
US4996335 (Pediatric) | Soft steroids having anti-inflammatory activity |
Sep 09, 2012
(Expired) | Bausch And Lomb |
| Lotemax | US5540930 | Suspension of loteprednol etabonate for ear, eye, or nose treatment |
Oct 25, 2013
(Expired) | Bausch And Lomb |
| Lotemax | US5540930 | Suspension of loteprednol etabonate for ear, eye, or nose treatment |
Oct 25, 2013
(Expired) | Pharmos |
| Lotemax |
US5540930 (Pediatric) | Suspension of loteprednol etabonate for ear, eye, or nose treatment |
Apr 25, 2014
(Expired) | Bausch And Lomb |
| Lotemax | US5747061 | Suspension of loteprednol etabonate for ear, eye, or nose treatment |
Oct 25, 2013
(Expired) | Bausch And Lomb |
| Lotemax |
US5747061 (Pediatric) | Suspension of loteprednol etabonate for ear, eye, or nose treatment |
Apr 25, 2014
(Expired) | Bausch And Lomb |
| Lotemax | US5800807 | Ophthalmic compositions including glycerin and propylene glycol |
Jan 29, 2017
(Expired) | Bausch And Lomb Inc |
| Lotemax Sm | US10596107 | Ophthalmic suspension composition | Dec 23, 2036 | Bausch And Lomb Inc |
| Lotemax Sm | US11534395 | Ophthalmic suspension composition | Jan 26, 2036 | Bausch And Lomb Inc |
Coming Soon
Patent Strength Analyzer
YesNo
Thank you for your response 🥳
Loteprednol Etabonate Generics
Several generic applications have been filed for Loteprednol Etabonate. The first generic version for Loteprednol Etabonate was by Sentiss Ag and was approved on Apr 17, 2019. And the latest generic version is by Padagis Us Llc and was approved on Jul 10, 2024.
Given below is the list of companies who have filed for Loteprednol Etabonate generic.
1. HIKMA
Hikma Pharmaceuticals Usa Inc has filed for 1 generic for Loteprednol Etabonate. Given below are the details of the strengths of this generic introduced by Hikma.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 0.5% | gel | Prescription | OPHTHALMIC | AB | Nov 29, 2023 |
2. LUPIN LTD
Lupin Ltd has filed for 2 different strengths of generic version for Loteprednol Etabonate. Given below are the details of the strengths of this generic introduced by Lupin Ltd.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 0.2% | suspension/drops | Prescription | OPHTHALMIC | AB | Dec 26, 2023 |
| 0.5% | suspension/drops | Prescription | OPHTHALMIC | AB | Apr 24, 2024 |
3. SUN PHARM
Sun Pharmaceutical Industries Ltd has filed for 1 generic for Loteprednol Etabonate. Given below are the details of the strengths of this generic introduced by Sun Pharm.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 0.5% | gel | Prescription | OPHTHALMIC | AB | Aug 9, 2023 |
4. SENTISS
Sentiss Ag has filed for 2 different strengths of generic version for Loteprednol Etabonate. Given below are the details of the strengths of this generic introduced by Sentiss.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 0.5% | gel | Prescription | OPHTHALMIC | AB | Feb 10, 2021 |
| 0.2% | suspension/drops | Prescription | OPHTHALMIC | AB | Apr 12, 2023 |
5. PADAGIS US
Padagis Us Llc has filed for 1 generic for Loteprednol Etabonate. Given below are the details of the strengths of this generic introduced by Padagis Us.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 0.2% | suspension/drops | Prescription | OPHTHALMIC | AB | Jul 10, 2024 |